Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9NS23: Variant p.Lys21Gln

Ras association domain-containing protein 1
Gene: RASSF1
Feedback?
Variant information Variant position: help 21 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Lysine (K) to Glutamine (Q) at position 21 (K21Q, p.Lys21Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (K) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 21 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 344 The length of the canonical sequence.
Location on the sequence: help MSGEPELIELRELAPAGRAG K GRTRLERANALRIARGTACN The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         MSGEPELIELRELAPAGRA------GKGRTRLE--------------RANALRIARGTACN

Mouse                         MSAEPELIELRELAPSGRI------GPGRTRLE--------

Caenorhabditis elegans        VATDDPTYQSYAFQPSTSSSNISWFGGLRTKLSQLSLFPDW

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Initiator methionine 1 – 1 Removed
Chain 2 – 344 Ras association domain-containing protein 1
Region 2 – 119 Mediates interaction with E4F1
Modified residue 2 – 2 N-acetylserine
Modified residue 2 – 2 Phosphoserine
Modified residue 36 – 36 Omega-N-methylarginine
Alternative sequence 1 – 155 Missing. In isoform B.
Alternative sequence 1 – 74 Missing. In isoform C and isoform H.



Literature citations
Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
Dammann R.; Li C.; Yoon J.-H.; Chin P.L.; Bates S.; Pfeifer G.P.;
Nat. Genet. 25:315-319(2000)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A; B AND C); FUNCTION; TISSUE SPECIFICITY; VARIANT GLN-21; INTERACTION WITH XPA; Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.
Burbee D.G.; Forgacs E.; Zochbauer-Muller S.; Shivakumar L.; Fong K.; Gao B.; Randle D.; Kondo M.; Virmani A.; Bader S.; Sekido Y.; Latif F.; Milchgrub S.; Toyooka S.; Gazdar A.F.; Lerman M.I.; Zabarovsky E.; White M.; Minna J.D.;
J. Natl. Cancer Inst. 93:691-699(2001)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A; C; D; E; F AND G); FUNCTION; TISSUE SPECIFICITY; VARIANTS GLN-21; CYS-53; GLU-133; SER-137 AND CYS-329;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.